000_cdcdc

COVID-19 less severe in paediatric patients, according to the CDC

pharmafile | April 8, 2020 | News story | Research and Development COVID-19, coronavirus 

The Centers for Disease Control and Prevention (CDC) confirms that COVID-19 is less severe in children than adults.

The report, called Coronavirus Disease 2019 in Children, showed that fewer children with coronavirus where hospitalised. The report also shows that children were far less likely to show symptoms but they still can become seriously ill and hospitalised.

The report analysed 2,572 cases of COVID-19 in children as part of 149,760 laboratory confirmed cases. The median age of the study was 11. Overall 73% of children had symptoms compared to 93% of adult aged 18-64 during the same period. 56% of children in this study reported fever, 54% reported having a cough and 13% reported they had a shortness of breath.

Only 5.7% of all these patients were hosptialised compared to 33% of adults, with patients less than 1 were the highest percentage of hospitalised children.

The CDC commented on the study and said: “These data support previous findings that children with COVID-19 might not have reported fever or cough as often as do adults. Whereas most COVID-19 cases in children are not severe, serious COVID-19 illness resulting in hospitalization still occurs in this age group.” 

33% of children in this study were from New York City, 23% were from the rest of New York State, 15% were from New Jersey and the remaining 29% were from other US states.

Conor Kavanagh

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …

Latest content